Skip to content

Adjuvant Antifungal Therapy Using Tissue Tolerable Plasma on Oral Mucosa and Removable Dentures in Oral Candidiasis Patients: A Double-Blinded Split-Mouth Pilot Study.

Adjuvant Antifungal Therapy Using Tissue Tolerable Plasma on Oral Mucosa and Removable Dentures in Oral Candidiasis Patients: A Double-Blinded Split-Mouth Pilot Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00009368
Enrollment
8
Registered
2015-09-21
Start date
2015-03-11
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B37.0

Interventions

Group 1: In clinical routine decontamination of the oral mucosa and prostheses with cold plasma is not performed so far. In patients with suspected diagnosis of oral candidiasis in the upper jaw, a mi

Sponsors

Charité Campus Benjamin Franklin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: Patients eligible for inclusion were able to give informed consent, were between 18 and 95 years old and non-smokers (for =5 years). All patients wore removable prostheses, partially or totally covering the upper alveolar ridge and/or hard palate. Confirmation of diagnosis assumed from clinical signs of infection (at least in terms of erythematous maculae or zones but possibly hyperplasia or complaints as well) via Candida detection was required. Hence, all subjects were diagnosed with denture stomatitis Newton-level 1, 2 or 3 based on both positive clinical and paraclinical findings.

Exclusion criteria

Exclusion criteria: Patients having suffered from any malignant tumor within the last five years or suffering from severe general diseases (American Society of Anesthesiologists (ASA) risk class = 3, myocardial infarction within the last six months, cardiomyopathy, New York Heart Association (NYHA) cardiac insufficiency stage = III, chronic obstructive pulmonary disease (COPD), renal insufficiency, diabetes mellitus (HbA1c = 7%), sickle-cell anemia, rheumatoid arthritis, status post radiation or organ transplantation, malnutrition) were excluded from the study. Furthermore, pacemaker carriers, pregnant women, smokers, alcoholics and drug users were not eligible.

Design outcomes

Primary

MeasureTime frame
At the end of treatment after six-time plasma application there is a remission of erythema. The evaluation is carried out using a digital measurement of the photographs made.

Secondary

MeasureTime frame
At the end of treatment after six-time plasma application Candida spp. can not or only sporadically be detected. A mouth swab confirms this. There is a reduction in VAS scores in cases with existing complaints. These are collected once a week.

Countries

Germany

Contacts

Public ContactSaskia Preissner

Charité Campus Benjamin Franklin; CC3 - Zahn-, Mund- und Kieferheilkunde

saskia.preissner@charite.de+4930450562675

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026